Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline

• DOI: 10.1111/exd.13065
• Publication Date: 2016-05-19T18:01:52Z
• Authors: Anne C. Knol; Audrey Vallée; Guillaume Herbreteau; Jean‐Michel Nguyen; Emilie Varey; Aurélie Gaultier; Sandrine Théoleyre; Mélanie Saint‐Jean; Lucie Peuvrel; Anabelle Brocard; Gaëlle Quéreux; Amir Khammari; Marc G. Denis; Brigitte Dréno
• Keywords: Circulating tumor DNA; Refractory (planetary science)

Abstract Circulating tumor DNA is a promising non‐invasive tool for cancer monitoring. The main objective of our work was to investigate the relationship between mutant BRAF in plasma and clinical response. Thirty‐eight stage IV patients with V600 mutated melanoma were included prior any treatment. extracted from detected using amplification‐refractory mutation system method. Before beginning treatment, corresponding 29 38 tested samples (76.3% positive per cent agreement). We observed strong correlation presence circulating overall survival ( OS ; P =.02), number metastatic sites =.01). also strongly correlated serum LDH activity <.01) S100 protein concentration <.01). Finally, seven presented discordant status different sites. In all these patients, test performed on ct positive, suggesting that analysis might be less sensitive heterogeneity. Altogether, results suggest plasmatic prognostic factor , burden. addition, it represents an interesting alternative source detect mutations before